Lung Cancer News and Research

Latest Lung Cancer News and Research

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

22 Oct 2018

Study findings could set new standard of care for advanced anal cancer

A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010

Air pollution in the U.S. has decreased since about 1990, and a new study conducted at the University of North Carolina at Chapel Hill now shows that this air quality improvement has brought substantial public health benefits.

20 Oct 2018

New approach to understanding cancers will accelerate development of better treatments

A new innovation in cancer research will enable scientists to understand the complex causes of the disease with unprecedented speed and sophistication. This will accelerate the development of new and better treatments, and it will help researchers find ways around roadblocks that now stand in their path.

19 Oct 2018

Report predicts life expectancy in 2040, Spain comes out on top

A new report from the Institute for Health Metrics and Evaluation (IHME) states that people born and living in Spain, Japan, and China are likely to live longer than those born and living in the United States.

18 Oct 2018

Novel method uses just a drop of blood to monitor effect of lung cancer therapy

Dr Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of which was nivolumab (Opdivo).

17 Oct 2018

Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features

A study comparing DNA and RNA data from Nigerian breast cancer patients to patients in a United States database found that certain aggressive molecular features were far more prevalent in tumors from Nigerian women than in black or white American women.

16 Oct 2018

Health effects of smoke-filled atmosphere

Every day, every human on the planet is exposed to one of the most toxic substances we know. However, it's largely invisible and most people don't know whether they need to worry. In new book Particles in the Air, Doug Brugge aims to raise awareness of serious consequences for public health.

16 Oct 2018

Modeling Non-Numerical Data in Systems Biology

An interview with Dr. Eshan Mitra, discussing the importance of computer models in biology and the development of a more accurate model of the RAF phosphorylation pathway.

15 Oct 2018

Lung cancer mortality rates are 28% lower in California

Early adoption of tobacco control efforts in California lead to fewer people ever smoking, reduced the amount used by those who do smoke and helped smokers quit at a younger age -- when their risk of developing lung cancer is lowest.

11 Oct 2018

Tobacco control must be highest priority in national cancer control plan, says report

The highest priority in a national cancer control plan must be expansion of tobacco control--the intervention with the largest potential health benefits--according to a new American Cancer Society report, the second in a series of articles that together inform priorities for a comprehensive cancer control plan.

11 Oct 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.

10 Oct 2018

Lung Cancer News and Research

Latest Lung Cancer News and Research

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Study: Targeting specific genomic mutation in breast cancer improves survival

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Study findings could set new standard of care for advanced anal cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010

New approach to understanding cancers will accelerate development of better treatments

Report predicts life expectancy in 2040, Spain comes out on top

Novel method uses just a drop of blood to monitor effect of lung cancer therapy

Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features

Health effects of smoke-filled atmosphere

Modeling Non-Numerical Data in Systems Biology

Lung cancer mortality rates are 28% lower in California

Tobacco control must be highest priority in national cancer control plan, says report

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in